Incidence of sexually transmitted infections and screening models among pre-exposure prophylaxis users.

Oskar Ayerdi, Eva Orviz, Adrián Valls Carbó, Nuria Fernández Piñeiro, Mar Vera García, Teresa Puerta López, Juan Ballesteros Martín, Carmen Rodríguez Martín, Begoña Baza Caraciolo, Clara Lejarraga Cañas, Jorge-Alfredo Pérez-García, Dulce Carrió, Mónica García Lotero, María Ferreras Forcada, Montserrat González Polo, Montserrat Raposo Utrilla, Alberto Delgado-Iribarren, Jorge Del Romero-Guerrero, Vicente Estrada Pérez
Author Information
  1. Oskar Ayerdi: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  2. Eva Orviz: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: evaorviz@gmail.com.
  3. Adrián Valls Carbó: Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.
  4. Nuria Fernández Piñeiro: Servicio de Farmacia, Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  5. Mar Vera García: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  6. Teresa Puerta López: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  7. Juan Ballesteros Martín: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  8. Carmen Rodríguez Martín: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  9. Begoña Baza Caraciolo: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  10. Clara Lejarraga Cañas: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  11. Jorge-Alfredo Pérez-García: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain; Servicio Microbiología Clínica, Instituto Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain.
  12. Dulce Carrió: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  13. Mónica García Lotero: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  14. María Ferreras Forcada: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  15. Montserrat González Polo: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  16. Montserrat Raposo Utrilla: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  17. Alberto Delgado-Iribarren: Servicio Microbiología Clínica, Instituto Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain.
  18. Jorge Del Romero-Guerrero: Centro Sanitario Sandoval, IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
  19. Vicente Estrada Pérez: Hospital Clínico San Carlos, IdISSC, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Madrid, Spain.

Abstract

INTRODUCTION: There is discussion about the frequency of STI screening among pre-exposure prophylaxis (PrEP) users. The aim of this study was to analyse the incidence of STIs and to evaluate different screening models in order to optimise the follow-up.
METHODOLOGY: A prospective study was conducted between 2017 and 2023, including 138 PrEP users in a STI clinic. Participants were tested for STIs every three months. Unscheduled visits were performed for those with STI-related symptoms or for people who were notified for an STI by a sexual partner. We performed a survival analysis of repeated events, estimating the cumulative incidence (CI) and incidence rate (IR).
RESULTS: The overall CI by quarterly screening was 8.3 (95% CI: 7.6-9.1) infections per person over six years, with a decreasing trend. The most frequently diagnosed pathogen was Neisseria gonorrhoeae, with a IR of 0.76 (95% CI: 0.68-0.84). If the frequency of screening is reduced to every six months, the IR of STIs is reduced by (95% CI: 0.5-0.66) infections per user per year, and at 12 months by 0.82 (95% CI: 0.73-0.89). In the case of no pharyngeal or urethral screening, IR is reduced by 0.37 (95% CI: 0.32-0.42) infections per person per year and in those over 35 years of age by 0.33 (95% CI: 0.25-0.4). Eliminating unscheduled visits, the reduction in IR is 0.33 (95% CI: 0.24-0.42).
CONCLUSIONS: The incidence of STIs among PrEP users is high, especially in the rectum, but it does not increase over time. STI screening could be optimised reducing the frequency of pharyngeal and urethral testing, particularly in those over 35 years of age. It is essential to redistribute health resources for unscheduled visits, which have been shown to be the most cost-effective screening.

Keywords

MeSH Term

Humans
Incidence
Sexually Transmitted Diseases
Prospective Studies
Male
Adult
Pre-Exposure Prophylaxis
Female
Mass Screening
Young Adult
Middle Aged
Adolescent

Word Cloud

Created with Highcharts 10.0.00screening95%CI:IRinfectionsperSTIusersincidenceSTIsfrequencyamongprophylaxisPrEPmonthsvisitsyearsreducedpre-exposurestudymodelseveryperformedsexualCIpersonsixyearpharyngealurethral4235age33unscheduledtransmittedINTRODUCTION:discussionaimanalyseevaluatedifferentorderoptimisefollow-upMETHODOLOGY:prospectiveconducted20172023including138clinicParticipantstestedthreeUnscheduledSTI-relatedsymptomspeoplenotifiedpartnersurvivalanalysisrepeatedeventsestimatingcumulativerateRESULTS:overallquarterly8376-91decreasingtrendfrequentlydiagnosedpathogenNeisseriagonorrhoeae7668-0845-066user128273-089case3732-025-04Eliminatingreduction24-0CONCLUSIONS:highespeciallyrectumincreasetimeoptimisedreducingtestingparticularlyessentialredistributehealthresourcesshowncost-effectiveIncidencesexuallyCribadoInfeccionesdetransmisiónPre-exposureProfilaxispreexposiciónScreeningSexually

Similar Articles

Cited By